Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new glaucoma treatment could be on the horizon. The FDA has accepted a new drug application for K-911 (bimatoprost grenod), an investigational eye drop that lowers eye pressure through two distinct mechanisms. With a PDUFA date set for April 30, 2027, Kowa Pharmaceuticals is eyeing a U.S. launch in the second half of next year if approved.
The FDA has officially accepted a new drug application (NDA) for K-911 (also known as NCX 470 or bimatoprost grenod), an investigational eye drop developed for patients with open-angle glaucoma or ocular hypertension. Kowa Pharmaceuticals, which licensed the drug from Nicox, is targeting a U.S. launch in the second half of 2027 if the FDA grants approval.
What makes K-911 stand out is its dual-action approach: nitric oxide enhances aqueous humor outflow through the trabecular meshwork and Schlemm's canal, while bimatoprost simultaneously increases uveoscleral outflow — two complementary pathways for lowering intraocular pressure (IOP).
By the Numbers:
Why it matters: Open-angle glaucoma is a leading cause of irreversible blindness worldwide. A dual-mechanism drop that matches or outperforms the current standard of care could offer clinicians a more effective tool for managing IOP and preserving patients' vision.